Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

Are you ready to test your knowledge about cardiac involvement in Fabry?

Type 2 Asthma Remission: Latest Data

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

Type 2 Asthma Remission: Latest Data

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

Type 2 Asthma Remission: Latest Data

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

Lęk przed hipoglikemią jako bariera terapeutyczna: Jak skutecznie wspierać pacjentów w praktyce?

דגשים למניעה קרדיווסקולרית - מדריך כיס להורדה

ACS EuroPath Survey

Yapay Pankreas Nedir, Nasıl Çalışır?

Diyabet hastalarının hayatını tamamen değiştirebilecek yapay pankreas cihazı test ediliyor! Bir sensör ve insülin veren bir pompadan oluşan yapay pankreas cihazı, gerçek pankreasın görevini taklit ediyor.

Neurologische Manifestationen des Morbus Gaucher Typ 3

Beyfortus®: Insights from real-world studies (NIRSE-GAL & NirseCL)

Beyfortus®: Insights from real-world studies (NIRSE-GAL & NirseCL)

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers1,2